Fig. 1A



Goat α-mouse-IgG-FITC only
38SB13
38SB18
38SB19
300-19/CD38
300-19
Ramos
60
30
0
10 10¹ 10² 10³ 10⁴
FL1-Height

Fig. 1B







38SB30
38SB31
38SB39
AT13/5
300-19/ CD38
300-19
Ramos
60
30
0
10 10¹ 10² 10³ 10⁴
FL1-Height


Fig. 2


Relative Mean Fluorescence
mu38SB13
600
300
0
10-14
10-11
10-8
Concentration (M)


Relative Mean Fluorescence
mu38SB18
600
300
0
10-14
10-11
10-8
Concentration (M)


Relative Mean Fluorescence
mu38SB19
600
300
0
10-14
10-11
10-8
Concentration (M)


Relative Mean Fluorescence
mu38SB30
600
300
0
10-14
10-11
10-8
Concentration (M)


Relative Mean Fluorescence
mu38SB31
600
300
0
10-14
10-11
10-8
Concentration (M)



Relative Mean Fluorescence
mu38SB39
600
300
0
10-14
10-11
10-8
Concentration (M)

Fig. 3



1.43%
4.05%
1.82%
FL4H
FL1-H
untreated
1.25%
3.72%
3.38%
AT13/5
1.85%
10.60%
53.67%
38SB13
3.15%
9.43%
25.97%
38SB19
FL4-H (TO-PRO-3)
FL1-H (Annexin V)

Fig. 4A




Fig. 4B




Fig. 4C




Fig. 5A



NotI
hCMV
EcoRI
hu38SB19 LC var
BsiWI
K constant
BamHI
SV40 polyA
SV40 pro/ori crippled
DHFR
SV40 polyA
AMP
ColE1 ori
SV40 polyA
Zeo R
SV40 pro/ori
f1 origin
ps38SB19lcz1-0
8467 bp

Fig. 5B



SV40 PolyA
NotI
hCMV
HindIII
hu38SB19 HC var
ApaI
huIgG1 const
XhoI
Crippled SV40 ori
DHFR
SV40 PolyA
Amp R
Col E1 ori
SV40 ori
Neo R
ps38SB19hcn1-0
9081 bp

Fig. 5C



SV40 PolyA
NotI
hCMV
EcoRI
hu38SB19 LC var
BsiWI
K constant
BamHI
hCMV
HindIII
hu38SB19 HC var
ApaI
huIgG1 const
XhoI
Crippled SV40 ori
DHFR
SV40 PolyA
Amp R
Col E1 ori
SV40 ori
Neo R
ps38SB19v1-00
11324 bp

Fig. 6A



40
30
20
10
0
% Specific Lysis
10-6 10-5 10-4 10-3 10-2 10-1 100
Concentration (µg/ml)
ch38SB13
ch38SB18
ch38SB19

Fig. 6B



40
30
20
10
0
% Specific Lysis
10-6 10-5 10-4 10-3 10-2 10-1 100
Concentration (µg/ml)
ch38SB30
ch38SB31
ch38SB39

Fig. 7A



% Specific Lysis
40
30
20
10
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1}
Concentration (µg/ml)
ch38SB18
ch38SB19
ch38SB31
chIgG1 control

Fig. 7B



% Specific Lysis
50
40
30
20
10
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
Concentration (µg/ml)
ch38SB19
mu38SB19

Fig. 8A



% Specific Lysis
40
30
20
10
0
10^{-7} 10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
Concentration (μg/ml)
ch38SB19
chIgG1 control

Fig. 8B



% Specific Lysis
30
20
10
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
Concentration (μg/ml)
ch38SB19
chIgG1 control

Fig. 9 A



% Specific Viability
100
75
50
25
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0} 10^{1}
Concentration (µg/ml)
ch38SB13
ch38SB18
ch38SB19
ch38SB30
ch38SB39

Fig. 9 B



% Specific Viability
100
75
50
25
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
Concentration (µg/ml)
ch38SB19
ch38SB31

Fig. 10



% Specific Viability
100
75
50
25
0
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
Concentration (µg/ml)
ch38SB18
ch38SB19
ch38SB31
chIgG1 control

Fig. 11A




Fig. 11B




Fig. 11C



% Specific Viability
100
75
50
25
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101
Concentration (mg/ml)
ch38SB19
ch38SB31

Fig. 12A




Fig. 12B




Fig. 13



% Annexin V positive cells
70
60
50
40
30
20
10
0
10-8 10-9 10-10 10-11 10-8 10-9 10-10 10-11 10-8 10-9 10-10 10-11 0
ch38SB19
hu38SB19 v1.00
hu38SB19 v1.20
Concentration (M)

Fig. 14



% Specific Lysis
50
40
30
20
10
0
10-6 10-5 10-4 10-3 10-2 10-1 100
Concentration (µg/ml)
hu38SB19 v1.00
hu38SB19 v1.20
ch38SB19
chIgG1 control

Fig. 15A




Fig. 15B




Fig. 15C




Fig. 16



SU-DHL-8
% Annexin V positive cells
100
75
50
25
0
untreated
hu38SB19
NU-DUL-1
% Annexin V positive cells
45
40
35
30
25
20
15
10
5
0
untreated
hu38SB19
DND-41
% Annexin V positive cells
70
60
50
40
30
20
10
0
untreated
hu38SB19
JVM-13
% Annexin V positive cells
20
15
10
5
0
untreated
hu38SB19
HC-1
% Annexin V positive cells
12
10
8
6
4
2
0
untreated
hu38SB19

Fig. 17



% Survival
100
90
80
70
60
50
40
30
20
10
0
25
30
35
40
45
50
55
60
PBS
mu38SB13
mu38SB18
mu38SB19
mu38SB30
mu38SB31
mu38SB39
Days after iv tumor cell inoculation

Fig. 18



% Survival
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
PBS
hu38SB19
mu38SB19
Days after iv tumor cell inoculation

Fig. 19




Mean Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
25
50
75
100
Days (post inoculation)
PBS
hu38SB19
chIgG1

Fig. 20


Mean Tumor Volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
Days (post inoculation)
PBS
hu38SB19
mu38SB19
chIgG1